Gsa Capital Partners LLP Alkermes Plc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $553,256 - $801,466	25,148 New	25,148 $562,000
Q3 2021 Nov 12, 2021	SELL	$23.37 - $32.13 $1.51 Million - $2.08 Million	-64,673 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$18.78 - $25.15 $74,105 - $99,241	-3,946 Reduced 5.75%	64,673 $1.59 Million
Q1 2021 May 10, 2021	BUY	$18.21 - $23.2 $1.25 Million - $1.59 Million	68,619 New	68,619 $1.28 Million
Q4 2020 Feb 03, 2021	SELL	$15.39 - $22.1 $1.64 Million - $2.35 Million	-106,427 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$16.16 - $20.66 $1.72 Million - $2.2 Million	106,427 New	106,427 $1.76 Million
Q1 2020 May 12, 2020	SELL	$13.06 - $21.24 $1.17 Million - $1.9 Million	-89,331 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$17.29 - $21.74 $1.21 Million - $1.52 Million	69,842 Added 358.37%	89,331 $1.82 Million
Q3 2019 Nov 12, 2019	SELL	$19.51 - $24.28 $165,464 - $205,918	-8,481 Reduced 30.32%	19,489 $380,000
Q2 2019 Aug 06, 2019	BUY	$21.47 - $37.33 $600,515 - $1.04 Million	27,970 New	27,970 $630,000
Q1 2019 May 15, 2019	SELL	$28.4 - $36.49 $505,804 - $649,886	-17,810 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$27.94 - $44.61 $497,611 - $794,504	17,810 New	17,810 $526,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.84B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.